Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 7/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23217433 | 1.00 | HTR2C (0.40) | HTR2CHTR2AHTR2BGRIN2BDRD2 | |
| SCHEMBL23217149 | 0.87 | HTR2C (0.45) | HTR2CHTR2AHTR2BDRD2EGFR | |
| SCHEMBL23217279 | 0.87 | HTR2A (0.39) | HTR2CHTR2AHTR2BGRIN2BDRD2 | |
| SCHEMBL23217282 | 0.87 | HTR2A (0.39) | HTR2CHTR2AHTR2BGRIN2BDRD2 | |
| SCHEMBL28950070 | 0.86 | HTR2A (0.39) | HTR2CHTR2AHTR2B | |
| SCHEMBL25034722 | 0.86 | HTR2A (0.39) | HTR2CHTR2AHTR2B | |
| SCHEMBL23217190 | 0.86 | HTR2C (0.41) | HTR2CHTR2AHTR2BDRD2EGFR | |
| SCHEMBL23217318 | 0.85 | HTR2C (0.41) | HTR2CHTR2AHTR2BDRD2L3MBTL1 | |
| SCHEMBL23217480 | 0.80 | HTR2C (0.44) | HTR2CHTR2AHTR2BDRD2 | |
| SCHEMBL23217172 | 0.80 | HTR2C (0.44) | HTR2CHTR2AHTR2BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC | 2023-02-16 | — | — | US | disclosed |
| EP-4041405-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. Shaw Research, LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2021071832-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | D.E. SHAW RESEARCH, LLC (US) | 2021-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230049231-A1 | ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS | KCNB1, KCNJ2, KCNB2 | HTR2C 1162/4885HTR2A 1799/4885HTR2B 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.